drugset / Trial / NCT04294264
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
Phase 2
Active not recruiting
50 enrolled
Rutgers, The State University of New Jersey
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2019-02-12
- Primary completion
- 2024-03-27
- Completion
- 2026-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | Tipiracil | Small molecule | — | Oral |
| Subject | Trifluridine | Small molecule | — | Oral |